|Bid||58.00 x 1200|
|Ask||65.50 x 800|
|Day's Range||65.22 - 68.45|
|52 Week Range||26.13 - 107.69|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 08, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||85.80|
Castle presented data on its three skin cancer gene expression profile tests at the 10th World Congress of Melanoma.
Castle presented new data on the integration of the DecisionDx®-Melanoma test with clinicopathologic features (i31-GEP).
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced data from an independent, prospective study published in the American Journal of Surgery demonstrating DecisionDx®-Melanoma’s utility for prediction of outcomes in patients with cutaneous melanoma. DecisionDx-Melanoma is Castle’s gene expression profile test that uses an individual patient’s tumor biology to predict risk of cutaneous melanoma metastasis or recurrence, as well as sentinel lymph node positivity, independent of traditional staging factors.